Last reviewed · How we verify
Renacidin (CITRIC ACID)
Renacidin (generic name: CITRIC ACID) is a Anti-coagulant Small molecule drug developed by Baxter. It is currently FDA-approved (first approved 1982) for Calcium Phosphate Renal Calculi, Headache disorder, Indigestion.
Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones.
At a glance
| Generic name | CITRIC ACID |
|---|---|
| Sponsor | Baxter |
| Drug class | Anti-coagulant |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
XENLETA is an antibacterial drug [see Microbiology (12.4)].
Approved indications
- Calcium Phosphate Renal Calculi
- Headache disorder
- Indigestion
- Pain
- Struvite Renal Calculi
Common side effects
- Administration site reactions
- Diarrhea
- Hepatic enzyme elevation
- Nausea
- Hypokalemia
- Insomnia
- Headache
- Vomiting
- Anemia
- Atrial fibrillation
- Abdominal pain
- Alkaline phosphatase increased
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1,PHASE2)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Renacidin CI brief — competitive landscape report
- Renacidin updates RSS · CI watch RSS
- Baxter portfolio CI
Frequently asked questions about Renacidin
What is Renacidin?
Renacidin (CITRIC ACID) is a Anti-coagulant drug developed by Baxter, indicated for Calcium Phosphate Renal Calculi, Headache disorder, Indigestion.
How does Renacidin work?
Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones.
What is Renacidin used for?
Renacidin is indicated for Calcium Phosphate Renal Calculi, Headache disorder, Indigestion, Pain, Struvite Renal Calculi.
Who makes Renacidin?
Renacidin is developed and marketed by Baxter (see full Baxter pipeline at /company/baxter).
What is the generic name of Renacidin?
CITRIC ACID is the generic (nonproprietary) name of Renacidin.
What drug class is Renacidin in?
Renacidin belongs to the Anti-coagulant class. See all Anti-coagulant drugs at /class/anti-coagulant.
When was Renacidin approved?
Renacidin was first approved on 1982.
What development phase is Renacidin in?
Renacidin is FDA-approved (marketed).
What are the side effects of Renacidin?
Common side effects of Renacidin include Administration site reactions, Diarrhea, Hepatic enzyme elevation, Nausea, Hypokalemia, Insomnia.
Related
- Drug class: All Anti-coagulant drugs
- Manufacturer: Baxter — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Calcium Phosphate Renal Calculi
- Indication: Drugs for Headache disorder
- Indication: Drugs for Indigestion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing